CRISPR Therapeutics AG’s decision to transition from two earlier gene-edited allogeneic CAR-T cell therapies to next-generation candidates may have come at an opportune time, as concerns have arisen about potential risks of secondary T-cell malignancies arising from autologous CAR-Ts, which could be problematic for efforts to expand those therapies from hematology-oncology and into rheumatology. It also gives the company a chance to differentiate itself in an increasingly crowded space in B-cell malignancies.
The Swiss biotech announced the changes to its CAR-T pipeline on 4 December, saying it would transition its development efforts from two existing candidates, the CD19-targeting CTX110 and the CD70-targeting CTX130, to two new ones, CTX112 and CTX131, which respectively target the same antigens
Key Takeaways
-
CRISPR said it would refocus development from its first-generation, allogeneic gene-edited CAR-Ts to next-generation candidates.
-
The company plans to expand one candidate into lupus and another from a solid tumor trial into B- and T-cell malignancies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
